DETROIT — Standing on the front lawn of a home in a Detroit neighborhood, Republican U.S. Senate nominee Mike Rogers brought together a group of Democrats who on Thursday said they would vote for the former congressman instead of Abdul El-Sayed, the Democratic nominee. The coalition, known as “Democrats for Rogers,” currently consists of a […]
County's Juvenile Probation Agency Selects SuperCom's PureOne GPS Technology Following Multi-Week Live-Unit Evaluation
Patients are expected to enroll in the post-marketing study in the coming weeks, following approval from the Institutional Review Board of West Cancer Center & Research Institute in Germantown, TN
On Friday, July 31, 2026, Lieutenant Commander James M. Ennes, Jr., U.S. Navy, ret., slipped his cable and unfurled his sails. With the Great Pilot at the helm, he set a course to his final home port.
The McCord Stewart Museum revised information it had posted regarding the murder of Israeli athletes at the 1972 Olympic Games in Munich. A Montreal journalist who had scrolled though the online version of the museum’s exhibit commemorating the 1976 Montreal games noticed that the massacre had been glossed over. She brought it to the museum’s attention.
SINGAPORE, Aug. 19, 2026 /PRNewswire/ -- Kenon Holdings Ltd. (NYSE: KEN) (TASE: KEN) ("Kenon") announces that the Republic of Peru has paid the award rendered in the arbitration proceedings before an International Centre for Settlement of Investment Disputes tribunal (the "Tribunal"), which award was issued in favor of Kenon by the Tribunal in October 2023 (the "Award"). The total payment was approximately $203 million, of which Kenon's share (after allocation of a portion of the proceeds to a capital provider and payment of certain expenses) is approximately $93 million, subject to tax. The payment reflects final payment of amounts payable by the Republic of Peru in connection with the Award and conclusion of this matter.
TYSONS CORNER, Va. and PETAH TIKVA, Israel, Aug. 19, 2026 /PRNewswire/ -- Cellebrite DI Ltd. (Nasdaq: CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors, today announced that Cellebrite Genesis is expanding to more global markets and is now generally available for enterprise organizations. The expansion builds on a successful early access program and strong momentum following Genesis' June 2026 public safety launch. Genesis has seen meaningful user growth worldwide and continues to expand internationally, with availability now in Australia and the United Kingdom and is expected to be available to the European Union later this month.
TYSONS CORNER, Va. and PETAH TIKVA, Israel, Aug. 19, 2026 /PRNewswire/ -- Cellebrite DI Ltd. (Nasdaq: CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors, today announced that Cellebrite Genesis is expanding to more global markets and is now generally available for enterprise organizations. The expansion builds on a successful early access program and strong momentum following Genesis' June 2026 public safety launch. Genesis has seen meaningful user growth worldwide and continues to expand internationally, with availability now in Australia and the United Kingdom and is expected to be available to the European Union later this month.
TYSONS CORNER, Va. and PETAH TIKVA, Israel, Aug. 19, 2026 /CNW/ -- Cellebrite DI Ltd. (Nasdaq: CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors, today announced that Cellebrite Genesis is expanding to more global markets and is now generally available for enterprise organizations. The expansion builds on a successful early access program and strong momentum following Genesis' June 2026 public safety launch. Genesis has seen meaningful user growth worldwide and continues to expand internationally, with availability now in Australia and the United Kingdom and is expected to be available to the European Union later this month.
The prospective, single-arm study enrolled 32 colorectal cancer patients at three leading clinical centers in Israel. The primary objective was to demonstrate feasibility of intraoperative quantitative measurement of colon tissue quality.The study establishes the clinical foundation for novel intraoperative tissue assessment technology, with an aim to expand Colospan's product pipeline with a second technology platform for Colorectal Surgery.The new technology platform, which complements Colospan's CG-100 intraluminal bypass device, is designed to advance Galmed's strategy to build a leading innovative medtech and biotech company addressing unmet needs in GI oncology and colorectal surgery.
